Novartis turns to Oxford BioMedica for a major CAR-T supply deal
Oxford BioMedica has scored a major supply contract with Novartis for the lentiviral vectors the pharma giant uses in its CAR-T drugs, including the industry-leading CTL019, now under FDA review.
Oxford BioMedica is getting a $10 million payday to get the alliance started, and says it can earn up to $100 million over the course of the three-year pact. Novartis has an option to bump that to 5 years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.